Regeneron Pharmaceuticals (NASDAQ:REGN) Announces Quarterly Earnings Results, Beats Expectations By $3.56 EPS

Regeneron Pharmaceuticals (NASDAQ:REGN) announced its earnings results on Friday. The biopharmaceutical company reported $20.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $16.51 by $3.56, FiscalAI reports. The company had revenue of $5.12 billion for the quarter, compared to analysts’ expectations of $4.58 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The firm’s quarterly revenue was up 36.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $11.83 EPS.

Here are the key takeaways from Regeneron Pharmaceuticals’ conference call:

• Regeneron reported a strong third quarter, with total revenue up 36% to $5.1 billion and non-GAAP EPS up 70% to $20.07. Dupixent, EYLEA HD, and LIBTAYO each reached record quarterly sales.
• Dupixent sales grew 35% globally at constant currency to $6.5 billion, while U.S. EYLEA HD sales rose 62% to approximately $700 million and LIBTAYO sales increased 51% globally. Management expects continued EYLEA HD momentum and anticipates a potential prefilled-syringe approval before year-end.
• The pipeline produced encouraging data across several potential growth drivers, including approximately 70% liver-fat reduction for the genetically validated CIDEB siRNA, roughly 70% response rates for ubamatamab in low-grade serous ovarian cancer, and planned pivotal development for POTS and multiple myeloma programs.
• Regeneron expanded its Sanofi alliance to develop four next-generation, longer-acting type 2 inflammation antibodies, with Regeneron recording a $1 billion upfront payment in the fourth quarter and sharing future development costs and global profits equally.
• EYLEA’s U.S. sales fell 41% year over year to $400 million, with further low- to mid-teens sequential demand declines expected in the fourth quarter as aflibercept biosimilar competition increases. Regeneron also expects 2027 R&D expense to rise by a mid-teens percentage as it advances more than 15 Phase III trials.

Regeneron Pharmaceuticals Trading Up 13.3%

Shares of NASDAQ REGN traded up $109.12 during midday trading on Friday, reaching $927.89. 2,870,601 shares of the stock were exchanged, compared to its average volume of 632,332. The company has a 50 day simple moving average of $793.30 and a 200 day simple moving average of $738.05. The stock has a market capitalization of $95.53 billion, a P/E ratio of 22.93, a PEG ratio of 1.38 and a beta of 0.16. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34. Regeneron Pharmaceuticals has a twelve month low of $591.52 and a twelve month high of $935.35.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Q3 earnings and revenue beat expectations: Regeneron reported $5.12 billion in revenue, up 36.3% year over year and well above the approximately $4.56 billion analyst consensus. Non-GAAP EPS was $20.07, compared with estimates near $16.42 and $11.83 a year earlier. REGN Q3 Earnings Beat on Dupixent Profits & Eylea HD Growth, Stock Up
• Positive Sentiment: Strong commercial performance: Sanofi-partnered Dupixent generated robust demand, while U.S. Eylea HD sales increased 62% to $699 million and global Libtayo sales rose 51% to $550 million. The results suggest Regeneron’s product portfolio is offsetting competitive and pricing pressures in older treatments. Regeneron Reports Third Quarter 2026 Financial and Operating Results
• Positive Sentiment: Pipeline and strategic momentum: Regeneron highlighted progress toward upcoming FDA catalysts, expanded its Sanofi collaboration with next-generation long-acting immunology antibodies and received a $1 billion upfront payment to be recognized as collaboration revenue. A new Phase 2 cemiplimab combination study also expands its skin-cancer pipeline. Regeneron Expands Skin Cancer Pipeline With New Cemiplimab Combo Trial
• Neutral Sentiment: Management characterized 2026 as potentially one of Regeneron’s strongest years, and analysts have raised some expectations following the earnings beat. Investors will now focus on whether Dupixent growth and new launches can remain durable.
• Negative Sentiment: Eylea 2 mg remains exposed to biosimilar competition, while at least one analyst recently lowered Regeneron’s price target from $900 to $850. After the sharp upward move, valuation and the need for continued execution could create near-term volatility. Evercore ISI Adjusts Price Target on Regeneron Pharmaceuticals

Insider Activity

In related news, EVP Marion Mccourt sold 1,131 shares of the company’s stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $857.39, for a total value of $969,708.09. Following the transaction, the executive vice president directly owned 12,003 shares in the company, valued at approximately $10,291,252.17. This represents a 8.61% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total value of $340,000.00. Following the completion of the transaction, the director owned 603 shares of the company’s stock, valued at $512,550. The trade was a 39.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 8,093 shares of company stock worth $6,506,845 in the last 90 days. 6.97% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. Citigroup upped their price objective on shares of Regeneron Pharmaceuticals from $740.00 to $825.00 and gave the company a “neutral” rating in a research note on Friday. HSBC raised their target price on shares of Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the stock a “buy” rating in a research note on Thursday, September 10th. Morgan Stanley boosted their target price on Regeneron Pharmaceuticals from $758.00 to $779.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 7th. BMO Capital Markets upped their price target on Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the company an “outperform” rating in a research report on Wednesday, September 9th. Finally, Raymond James Financial increased their price target on Regeneron Pharmaceuticals from $902.00 to $911.00 and gave the company an “outperform” rating in a report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and eight have given a Hold rating to the company’s stock. According to MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $850.83.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.